Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

Pieris AG. (12/1/14). "Press Release: Pieris Achieves Second Preclinical Milestone Payment in Sanofi Collaboration". Freising.

Organisations Organisation Pieris AG
  Group Pieris (Group)
  Organisation 2 Sanofi S.A. (EURONEXT: SAN, NYSE: SNY)
  Group Sanofi (Group) [since May 2011]
Products Product Anticalin® therapeutic protein
  Product 2 drug discovery
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Schweitzer, Gretchen (MacDougall 201307 European Office)
     


Pieris AG announced the successful handover of a multispecific Anticalin® preclinical drug candidate from Pieris to Sanofi, who will be responsible for further development of the program, triggering an undisclosed payment to Pieris. The decision to advance the program is based on a positive review of a broad range of in vitro, in vivo and CMC data for the program. The multispecific polypeptide, comprising several unique Anticalins in one protein, is able to simultaneously engage several therapeutic targets.

"The Sanofi collaboration continues to push the Anticalin technology to new heights, and we're extremely proud to have built such a unique molecule with excellent drug-like properties," commented Stephen Yoder, CEO of Pieris. "Programs such as this one herald the differentiating power of our proprietary technology."

This program stems from the parties' R&D collaboration originally entered into in 2010, which involved an upfront payment to Pieris of EUR 3.5 million, committed research funding and payments for the achievement of research, preclinical, regulatory and commercial milestones. For this program, Pieris stands to receive up to EUR 26.5 million in development milestones for the first therapeutic application and EUR 18 million in commercial milestones, plus tiered royalties. Pieris would receive further milestones if Sanofi develops the program in multiple therapeutic applications.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms.


About Pieris

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalins promise to address high-unmet medical needs and expand the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. www.pieris.com.


For more information, please contact:

Stephen Yoder
CEO
Pieris AG
media@pieris.com
+49 (0) 8161 1411 400

Gretchen Schweitzer
gschweitzer@macbiocom.com
+49 172 861 8540

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px